Ionis Pharmaceuticals (IONS) EVP Devers Sells $59K of Stock

By TradeTexts Research Desk Oct 19, 2026, 10:02 PM EDT

Ionis Pharmaceuticals, Inc. (IONS) business photo

Key Points

Ionis Pharmaceuticals EVP and Chief Human Resources Officer Shannon L. Devers sold 1,357 shares on October 16, 2026, for about $59,082.
After the trade, Shannon L. Devers holds 17,811 $IONS shares, down 7.08% from before the trade.
The biotechnology company trades with a market cap around $7.38 billion and a next earnings report slated for November 4, 2026.
Wall Street analysts maintain a consensus buy rating on the stock with an average price target of $83.83.

Since the trade, $IONS is up 3.4% to date (from the $42.94 close on Oct 16, 2026).

Get Ionis Pharmaceuticals text alerts

We text you when insiders, Congress, analysts or big funds move on $IONS.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Ionis Pharmaceuticals, Inc. alert may contain errors. Disclosures

Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS) executive Shannon L. Devers sold 1,357 shares of company stock on October 16, 2026. The transaction was revealed in a Form 4 filing with the Securities and Exchange Commission.

IONS Ionis Pharmaceuticals, Inc.

$44.38 -44.30% year to date

Daily close · Oct 19, 2026

Inside Shannon L. Devers's Ionis Trade

Devers, who serves as the company's executive vice president and chief human resources officer, parted with the shares at an average price of $43.54 for a total value of $59,081.88. The sale reduced her direct holdings by 7.08%, leaving her with 17,811 shares after the transaction. The stock closed at $42.94 on the day of the trade.

Other Institutional Activity in Ionis Pharmaceuticals

Two Sigma Investments, LP grew its holdings by 394,798 shares, ending with 6,252,342 shares worth about $277,478,944. Royal Bank of Canada boosted its stake by 2,380,684 shares, finishing with 6,182,479 shares valued at approximately $274,378,424.

Ionis Pharmaceuticals, Inc. Stock Up 3.4%

The stock recently traded around $44.38 as of October 20, 2026, sitting above its event-day close and close to its 52-week low of $42.08. Shares trade below their 50-day moving average of $51.48 and well below their 200-day moving average of $68.43.

Recent Earnings

For the trailing twelve months, the company reported $874.09 million in revenue and an earnings per share loss of $3.48. Its net profit margin stood at -64.7% and return on equity was -105.5%. The next earnings report arrives on November 4, 2026.

Insider Buying and Selling at Ionis Pharmaceuticals, Inc.

Earlier insider trades at Ionis include CEO Brett Monia selling and buying shares in June, alongside purchases by EVP Eugene Schneider and EVP Joseph Baroldi.

Analysts Set New Price Targets

On September 9, 2026, Barclays maintained an overweight rating and trimmed its target to $85.00. Guggenheim kept a buy rating on September 15 with an $80.00 target. JP Morgan held an overweight rating on September 22 with a $70.00 target. HC Wainwright & Co. reiterated a buy rating on September 24 with a $100.00 target. Later, UBS upgraded the stock to buy on October 15 with an $88.00 target. The stock holds a consensus buy rating from 23 analysts with an average price target of $83.83.

About Ionis Pharmaceuticals

Based in Carlsbad, California, Ionis Pharmaceuticals develops RNA-targeted medicines to treat various severe illnesses. The commercial-stage biotechnology firm employs 1,480 people.

Bottom Line

Investors will watch for financial updates and pipeline progress when the company reports earnings on November 4, 2026. Executive transactions remain subject to individual financial planning and are reported via SEC filings.